Table A2.

Deaths on Study

Baseline ECOG PS	Primary Malignancy	Cause of Death	Time Since First Dose of Study Drug (weeks)	Time Since Initial Diagnosis (weeks)
0	Esophageal	PD	14.1	54.2
0	Gastric	PD	12.6	14.3
0	Gastric	PD	14.7	33.7
0	Pancreatic	GI perforation (attributed to capecitabine and sunitinib)	23.0	91.4
0	Unknown primary	Acute renal failure (attributed to disease under study)	5.6	21.7
1	Unknown primary	PD	6.6	46.5

Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; PD, progressive disease.